ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
1 hedge funds and large institutions have $17 invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
72% less capital invested
Capital invested by funds: $60 → $17 (-$43)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$42 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
RhumbLine Advisers
Boston,
Massachusetts
| $17 | -$42 | -72 | -71% |
|
ASLN Hedge Fund Activity: Q3 2025 in Review
1 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q3 2025, worth a combined $17 — down 72% from $60 a quarter earlier.
Fund positioning in ASLN was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was RhumbLine Advisers, cutting an estimated $42.
- 1 institutional investor held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $17 of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q3 2025, down 72% quarter-over-quarter.
- 0 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q3 2025 and 0 closed out.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q3 2025 was RhumbLine Advisers, an estimated $42 sold.
Based on aggregated 13F filings for Q3 2025.